Citigroup on Friday raised its price target for Biogen shares to $512 saying the data for BIIB037 "looks solid with far better efficacy than expected." The firm, however, points out the safety signals were more prominent. Citi views Alzheimer as a "sizable" opportunity for Biogen and keeps a Buy rating on the stock.
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here